1 / 24

Liquid Biopsy Market

The global liquid biopsy market was estimated to be at $2,508.2 million in 2021, which is expected to grow with a CAGR of 19.83% and reach $19,066.0 million by 2032.

bisreports
Download Presentation

Liquid Biopsy Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. res Liquid Biopsy Market - A Global and Regional Analysis Table of Content Attribution: https://pixabay.com/photos/tire-rim-car-mechanic-114259/ Focus on Offering, Usage, Workflow, Circulating Biomarker, Sample, Technology, Clinical GLOBAL LIQUID BIOPSY MARKET Application, End User, and Region Analysis and Forecast: 2022-2032 May 2022 All rights reserved at BIS Research Inc. 1

  2. BIS Research is a leading market intelligence and technology research company. BIS Research publishes in- depth market intelligence reports focusing on the market estimations, technology analysis, emerging high- growth applications, deeply segmented granular country-level market data and other important market parameters useful in the strategic decision making for senior management. BIS Research provides multi-client reports, company profiles, databases, and custom research services. Copyright © 2022 BIS Research Inc. GLOBAL LIQUID BIOPSY MARKET All Rights Reserved. This document contains highly confidential information and is the sole property of BIS Research. Disclosing, copying, circulating, quoting, or otherwise reproducing any or all contents of this document is strictly prohibited. Access to this information is provided exclusively for the benefit of the people or organization concerned. It may not be accessed by or offered, whether for sale or otherwise, to any third party. All rights reserved at BIS Research Inc. 2

  3. Table of Content Executive Summary .......................................................................... 25 1.Market ....................................................................................... 36 1.1 Product Definition ............................................................................................ 37 Inclusion and Exclusion .................................................................................. 37 2.Market Scope ............................................................................ 38 1.2 2.1 Key Questions Answered in the Report......................................................... 39 3.Research Methodology .............................................................. 40 3.1 Data Sources .................................................................................................... 41 3.1.1Primary Data Source ................................................................................... 41 3.1.2Secondary Data Sources ............................................................................ 42 3.2 Market Estimation Model ................................................................................. 42 3.3 Criteria for Company Profiling ........................................................................ 44 4.Market Overview ........................................................................ 45 4.1 Addressable Market Size and Growth Potential ............................................ 46 4.2 COVID-19 Impact on Global Liquid Biopsy Market ....................................... 47 4.2.1Impact on Market Size ................................................................................. 48 5.Industry Insights ........................................................................ 50 5.1 Recently Launched Product/Services ............................................................ 50 5.1.1Recently Launched Product/Services by Major Players .......................... 50 5.2 Regulatory Framework .................................................................................... 51 5.2.1Regulatory Framework in the U.S .............................................................. 51 5.2.1.1 Guidelines Recommendation ............................................................................. 51 GLOBAL LIQUID BIOPSY MARKET 5.2.2Regulatory Framework in the European Union (EU) ................................ 51 5.2.3Regulation in Other Countries.................................................................... 52 5.3 Reimbursement Scenario ................................................................................ 52 5.4 Financing Scenario .......................................................................................... 53 5.4.1Key Players Patent Portfolio ...................................................................... 53 5.4.2Key Players Stratification As per Raised Financing Value ...................... 55 All rights reserved at BIS Research Inc. 3

  4. 5.4.3Key Players Financing Analysis (by Company) ........................................ 55 5.4.4Financing Analysis, $Million, FY2019-FY2022 .......................................... 56 5.5 Supply Chain Analysis .................................................................................... 57 5.6 Product Mapping Analysis .............................................................................. 58 5.6.1By Technology ............................................................................................. 58 5.6.2By Sample Type ........................................................................................... 59 5.6.3By Circulating Biomarker ........................................................................... 61 5.6.4By Application ............................................................................................. 62 5.7 Global Liquid Biopsy Market: Stakeholder Analysis (N=30) ........................ 63 5.7.1Physicians’ Perception ............................................................................... 63 5.7.1.1 Technology Used for Liquid Biopsy ................................................................... 63 5.7.1.2 Factors Increasing the Adoption of NGS Based Liquid Biopsy .......................... 64 5.7.1.3 Treatment Guidelines for Different Types of Cancer ......................................... 65 5.7.1.4 Challenges for Liquid Biopsy ............................................................................. 65 5.7.2Payer’s Perception ...................................................................................... 66 5.7.2.1 Average Cost by Technology (N=30) ................................................................ 66 5.7.2.2 Cost Difference across End Users ..................................................................... 67 5.7.2.3 Key Factors for Determining Reimbursement Possibility ................................... 67 5.7.3Investors’ Perception .................................................................................. 68 Liquid Biopsy Government Initiatives ........................................................... 69 6.Market Dynamics ....................................................................... 70 5.8 6.1 Market Drivers .................................................................................................. 70 6.1.1Rising Cancer Prevalence .......................................................................... 70 6.1.2Increasing Adoption of Inorganic Growth Strategies in the Market ........ 72 GLOBAL LIQUID BIOPSY MARKET 6.1.3Increased Research Funding from National Cancer Institute ................. 73 6.2 Market Challenges ........................................................................................... 75 6.2.1Uncertain Reimbursement and Regulatory Policies ................................ 75 6.2.2Expected Implementation of Patient Protection and Affordable Care Act in the U.S ............................................................................................... 75 6.3 Market Opportunities ....................................................................................... 75 All rights reserved at BIS Research Inc. 4

  5. 6.3.1Potential Cost Savings ................................................................................ 75 6.3.2Existing Applicability in Non-Availability of Tissue Sections for Conventional Biopsy Approaches ............................................................. 76 7.Competitive Insights .................................................................. 77 7.1 Corporate Strategies ....................................................................................... 77 7.1.1Synergistic Activities .................................................................................. 77 7.1.2Acquisitions ................................................................................................. 78 7.1.3Funding and Business Expansion Activities ............................................ 79 7.2 Business Strategies ........................................................................................ 80 7.2.1Service/Product Launches ......................................................................... 80 7.3 Market Share Analysis (by Manufacturers) ................................................... 81 Market Share Analysis (by Service Providers) .............................................. 82 8.Global Liquid Biopsy Market, by Offering, $Million, 2021-2032 .... 84 7.4 8.1 Overview ........................................................................................................... 85 8.2 Testing Service ................................................................................................ 86 8.3 Kits .................................................................................................................... 87 8.4 Platform ............................................................................................................ 88 Other Consumables ......................................................................................... 89 9.Global Liquid Biopsy Market, by Technology, $Million, 2021- 2032 .......................................................................................... 91 8.5 9.1 Overview ........................................................................................................... 92 9.2 Next-Generation Sequencing .......................................................................... 92 9.3 Polymerase Chain Reaction ............................................................................ 93 9.3.1Digital PCR ................................................................................................... 94 GLOBAL LIQUID BIOPSY MARKET 9.3.2Multiplex PCR .............................................................................................. 95 9.3.3Real-Time PCR ............................................................................................. 96 9.3.4Others ........................................................................................................... 97 9.4 Other Technologies ......................................................................................... 98 9.5 Emerging Technologies .................................................................................. 99 10.Global Liquid Biopsy Market, by Workflow, $Million, 2021-2032 ................................................................................................ 100 All rights reserved at BIS Research Inc. 5

  6. 10.1Overview ......................................................................................................... 101 10.2Sample Preparation ....................................................................................... 102 10.3Library Preparation ........................................................................................ 102 10.4Sequencing .................................................................................................... 103 10.5Data Analysis and Management ................................................................... 105 11.Global Liquid Biopsy Market, by Usage, $Million, 2021-2032 .... 106 11.1Overview ......................................................................................................... 107 11.2Clinical ............................................................................................................ 108 11.3Research ........................................................................................................ 108 12.Global Liquid Biopsy Market, by Sample, $Million, 2021-2032 ... 110 12.1Overview ......................................................................................................... 111 12.2Blood .............................................................................................................. 112 12.3Urine ............................................................................................................... 112 12.4Saliva .............................................................................................................. 113 12.5Others ............................................................................................................. 114 13.Global Liquid Biopsy Market, by Circulating Biomarker, $Million, 2021-2032 .................................................................. 115 13.1Overview ......................................................................................................... 116 13.2Circulating Tumor Cells (CTCs) .................................................................... 117 13.3Cell-Free DNA (cfDNA) .................................................................................. 118 13.4Circulating Cell-Free RNAs ........................................................................... 118 13.5Exosomes and Extracellular Vesicles and Others ...................................... 119 13.6Other Circulating Biomarkers ....................................................................... 120 14.Global Liquid Biopsy Market, by Indication, $Million, 2021- 2032 ........................................................................................ 122 GLOBAL LIQUID BIOPSY MARKET 14.1Overview ......................................................................................................... 123 14.2Breast Cancer ................................................................................................ 124 14.3Prostate Cancer ............................................................................................. 125 14.4Lung Cancer ................................................................................................... 125 14.5Colorectal Cancer .......................................................................................... 126 All rights reserved at BIS Research Inc. 6

  7. 14.6Melanoma ....................................................................................................... 127 14.7Other Types of Cancer .................................................................................. 128 14.8Non-Oncology Disorder ................................................................................ 129 15.Global Liquid Biopsy Market, by Clinical Application, $Million, 2021-2032 ................................................................................ 130 15.1Overview ......................................................................................................... 131 15.2Treatment Monitoring .................................................................................... 132 15.3Prognosis and Recurrence Monitoring ........................................................ 132 15.4Treatment Selection ...................................................................................... 133 15.5Diagnosis and Screening .............................................................................. 134 16.Global Liquid Biopsy Market, by End User, $Million, 2021-2032 ................................................................................................ 136 16.1Overview ......................................................................................................... 137 16.1.1Academic and Research Institutions ....................................................... 138 16.1.2Clinical Laboratories ................................................................................. 138 16.1.3Pharmaceutical and Biotechnology Companies..................................... 139 16.1.4Other End Users ........................................................................................ 140 17.Region ..................................................................................... 141 17.1Overview ......................................................................................................... 142 17.2North America ................................................................................................ 144 17.2.1U.S. ............................................................................................................. 146 17.2.2Canada ....................................................................................................... 148 17.3Europe ............................................................................................................ 151 17.3.1Germany ..................................................................................................... 153 GLOBAL LIQUID BIOPSY MARKET 17.3.2France ......................................................................................................... 155 17.3.3U.K. ............................................................................................................. 156 17.3.4Italy ............................................................................................................. 158 17.3.5Spain ........................................................................................................... 159 17.3.6Rest-of-Europe........................................................................................... 160 17.4Asia-Pacific .................................................................................................... 163 All rights reserved at BIS Research Inc. 7

  8. 17.4.1China .......................................................................................................... 165 17.4.2Japan .......................................................................................................... 167 17.4.3India ............................................................................................................ 168 17.4.4Australia ..................................................................................................... 169 17.4.5South Korea ............................................................................................... 171 17.4.6Singapore ................................................................................................... 172 17.4.7Rest-of-Asia-Pacific ................................................................................... 173 17.5Latin America and Middle East ..................................................................... 175 17.5.1Brazil ........................................................................................................... 177 17.5.2Mexico ........................................................................................................ 178 17.5.3Saudi Arabia .............................................................................................. 180 17.5.4Rest-of-Latin America and Middle East ................................................... 181 17.6Rest-of-the-World .......................................................................................... 182 18.Market - Competitive Benchmarking & Company Profiles ......... 184 18.1Overview ......................................................................................................... 185 18.2Abcodia Ltd. ................................................................................................... 186 18.2.1Company Overview ................................................................................... 186 18.2.2Role of Abcodia Ltd. in the Liquid Biopsy Market .................................. 186 18.2.3Key Customers of the Company .............................................................. 186 18.2.4Key Competitors of the Company ............................................................ 187 18.2.5Corporate Strategies ................................................................................. 187 18.2.6Analyst Perspective .................................................................................. 188 18.3Bio-Rad Laboratories, Inc. ............................................................................ 189 18.3.1Company Overview ................................................................................... 189 GLOBAL LIQUID BIOPSY MARKET 18.3.2Role of Bio-Rad Laboratories, Inc. in the Global Liquid Biopsy Market ......................................................................................................... 189 18.3.3Key Competitors of the Company ............................................................ 189 18.3.4Key Customers of the Company .............................................................. 190 18.3.5Corporate Strategies ................................................................................. 190 18.3.6Financials ................................................................................................... 191 All rights reserved at BIS Research Inc. 8

  9. 18.3.7Key Insights about the Financial Health of the Company ...................... 193 18.3.8Analyst’s Perspective ............................................................................... 193 18.4Biocept, Inc. ................................................................................................... 194 18.4.1Company Overview ................................................................................... 194 18.4.2Role of Biocept, Inc. in the Global Liquid Biopsy Market ...................... 194 18.4.3Key Customers of the Company .............................................................. 194 18.4.4Key Competitors of the Company ............................................................ 194 18.4.5Corporate Strategies ................................................................................. 195 18.4.6Business Strategies .................................................................................. 195 18.4.7Financials ................................................................................................... 196 18.4.8Key Insights about the Financial Health of the Company ...................... 196 18.4.9Analyst’s Perspective ............................................................................... 197 18.5Dxcover Limited ............................................................................................. 198 18.5.1Company Overview ................................................................................... 198 18.5.2Role of Dxcover Limited in the Global Liquid Biopsy Market ................ 198 18.5.3Key Customers of the Company .............................................................. 198 18.5.4Key Competitors of the Company ............................................................ 198 18.5.5Dxcover Platform Workflow ...................................................................... 199 18.5.6Collaboration and Partnership of Dxcover Limited ................................ 200 18.5.7Corporate Strategies ................................................................................. 200 18.5.8Analyst Perspective .................................................................................. 201 18.6Elypta .............................................................................................................. 202 18.6.1Company Overview ................................................................................... 202 18.6.2Role of Elypta Limited in the Global Liquid Biopsy Market ................... 202 GLOBAL LIQUID BIOPSY MARKET 18.6.3Key Customers of the Company .............................................................. 202 18.6.4Key Competitors of the Company ............................................................ 202 18.6.5Corporate Strategies ................................................................................. 203 18.6.6Analyst’s Perspective ............................................................................... 203 18.7Epic Sciences ................................................................................................. 204 18.7.1Company Overview ................................................................................... 204 All rights reserved at BIS Research Inc. 9

  10. 18.7.2Role of Epic Sciences in the Global Liquid Biopsy Market ................... 204 18.7.3Key Customers of the Company .............................................................. 204 18.7.4Key Competitors of the Company ............................................................ 204 18.7.5Corporate Strategies ................................................................................. 205 18.7.6Analyst’s Perspective ............................................................................... 205 18.8F. Hoffmann-La Roche Ltd ............................................................................ 206 18.8.1Company Overview ................................................................................... 206 18.8.2Role of F. Hoffmann-La Roche Ltd in the Global Liquid Biopsy Market ......................................................................................................... 206 18.8.3Key Competitors of the Company ............................................................ 206 18.8.4Key Customers of the Company .............................................................. 206 18.8.5Business Strategies .................................................................................. 207 18.8.6Financials ................................................................................................... 207 18.8.7Key Insights about the Financial Health of the Company ...................... 209 18.8.8Analyst’s Perspective ............................................................................... 210 18.9Guardant Health ............................................................................................. 211 18.9.1Company Overview ................................................................................... 211 18.9.2Role of Guardant Health in the Global Liquid Biopsy Market ................ 211 18.9.3Key Customers of the Company .............................................................. 211 18.9.4Key Competitors of the Company ............................................................ 212 18.9.5Business Strategies .................................................................................. 212 18.9.6Financials ................................................................................................... 213 18.9.7Key Insights about the Financial Health of the Company ...................... 215 18.9.8Analyst’s Perspective ............................................................................... 215 GLOBAL LIQUID BIOPSY MARKET 18.10Illumina, Inc. ................................................................................................... 216 18.10.1 Company Overview ............................................................................. 216 18.10.2 Role of Illumina, Inc. in the Global Liquid Biopsy Market ............... 216 18.10.3 Key Competitors of the Company ..................................................... 216 18.10.4 Key Customers of the Company ........................................................ 216 18.10.5 Corporate Strategies ........................................................................... 217 All rights reserved at BIS Research Inc. 10

  11. 18.10.6 Financials ............................................................................................ 217 18.10.7 Key Insights about the Financial Health of the Company ............... 219 18.10.8 Analyst’s Perspective ......................................................................... 220 18.11Laboratory Corporation of America Holdings ............................................. 221 18.11.1 Company Overview ............................................................................. 221 18.11.2 Role of Laboratory Corporation of America Holdings in the Global Liquid Biopsy Market .................................................................... 221 18.11.3 Key Customers of the Company ........................................................ 221 18.11.4 Key Competitors of the Company ..................................................... 222 18.11.5 Corporate Strategies ........................................................................... 222 18.11.6 Financials ............................................................................................ 223 18.11.7 Analyst’s Perspective ......................................................................... 225 18.12LungLife AI, Inc. ............................................................................................. 226 18.12.1 Company Overview ............................................................................. 226 18.12.2 Role of LungLife AI, Inc. in the Global Liquid Biopsy Market ......... 226 18.12.3 Key Customers of the Company ........................................................ 226 18.12.4 Key Competitors of the Company ..................................................... 226 18.12.5 Corporate Strategies ........................................................................... 227 18.12.6 Analyst’s Perspective ......................................................................... 227 18.13Micronoma ...................................................................................................... 228 18.13.1 Company Overview ............................................................................. 228 18.13.2 Role of Micronoma in the Global Liquid Biopsy Market .................. 228 18.13.3 Key Competitors of the Company ..................................................... 228 18.13.4 Micronoma: Oncobiota Platform Design Overview .......................... 229 GLOBAL LIQUID BIOPSY MARKET 18.13.5 Research Partners of Micronoma ...................................................... 229 18.13.6 Investors of Micronoma ...................................................................... 230 18.13.7 Corporate Strategies ........................................................................... 230 18.13.8 Analyst Perspectives .......................................................................... 230 18.14Natera, Inc. ..................................................................................................... 231 18.14.1 Company Overview ............................................................................. 231 All rights reserved at BIS Research Inc. 11

  12. 18.14.2 Role of Natera, Inc. Limited in the Global Liquid Biopsy Market .... 231 18.14.3 Key Customers of the Company ........................................................ 232 18.14.4 Key Competitors of the Company ..................................................... 232 18.14.5 Corporate Strategies ........................................................................... 232 18.14.6 Financials ............................................................................................ 233 18.14.7 Key Insights about the Financial Health of the Company ............... 234 18.14.8 Analyst’s Perspective ......................................................................... 234 18.15Neogenomics Laboratories ........................................................................... 236 18.15.1 Company Overview ............................................................................. 236 18.15.2 Role of Neogenomics Laboratories in the Global Liquid Biopsy Market ......................................................................................................... 236 18.15.3 Key Competitors of the Company ..................................................... 236 18.15.4 Key Customers of the Company ........................................................ 236 18.15.5 Corporate Strategies ........................................................................... 237 18.15.6 Financials ............................................................................................ 237 18.15.7 Key Insights about the Financial Health of the Company ............... 238 18.15.8 Analyst’s Perspective ......................................................................... 239 18.16PerkinElmer Inc. ............................................................................................. 240 18.16.1 Company Overview ............................................................................. 240 18.16.2 Role of PerkinElmer Inc. in the Global Liquid Biopsy Market ......... 240 18.16.3 Key Competitors of the Company ..................................................... 240 18.16.4 Key Customers of the Company ........................................................ 240 18.16.5 Corporate Strategies ........................................................................... 241 18.16.6 Financials ............................................................................................ 241 GLOBAL LIQUID BIOPSY MARKET 18.16.7 Key Insights about the Financial Health of the Company ............... 243 18.16.8 Analyst’s Perspective ......................................................................... 244 18.17QIAGEN .......................................................................................................... 245 18.17.1 Company Overview ............................................................................. 245 18.17.2 Role of QIAGEN in the Global Liquid Biopsy Market ....................... 245 18.17.3 Key Competitors of the Company ..................................................... 245 All rights reserved at BIS Research Inc. 12

  13. 18.17.4 Key Customers of the Company ........................................................ 246 18.17.5 Corporate Strategies ........................................................................... 246 18.17.6 Business Strategies ............................................................................ 246 18.17.7 Financials ............................................................................................ 247 18.17.8 Key Insights about the Financial Health of the Company ............... 249 18.17.9 Analyst’s Perspective ......................................................................... 249 18.18Sysmex Corporation ...................................................................................... 251 18.18.1 Company Overview ............................................................................. 251 18.18.2 Role of Sysmex Corporation in the Global Liquid Biopsy Testing Market ......................................................................................................... 251 18.18.3 Key Competitors of the Company ..................................................... 251 18.18.4 Key Customers of the Company ........................................................ 251 18.18.5 Corporate Strategies ........................................................................... 252 18.18.6 Business Strategies ............................................................................ 252 18.18.7 Financials ............................................................................................ 253 18.18.8 Key Insights about the Financial Health of the Company ............... 254 18.18.9 Analyst’s Perspective ......................................................................... 255 18.19Thermo Fisher Scientific Inc. ........................................................................ 256 18.19.1 Company Overview ............................................................................. 256 18.19.2 Role of Thermo Fisher Scientific Inc. in the Global Liquid Biopsy Market ......................................................................................................... 256 18.19.3 Key Competitors of the Company ..................................................... 257 18.19.4 Key Customers of the Company ........................................................ 257 18.19.5 Corporate Strategies ........................................................................... 257 GLOBAL LIQUID BIOPSY MARKET 18.19.6 Financials ............................................................................................ 258 18.19.7 Key Insights about the Financial Health of the Company ............... 260 18.19.8 Analyst’s Perspective ......................................................................... 260 All rights reserved at BIS Research Inc. 13

  14. List of Figures Figure 1: Type of Cancer Diagnostics Figure 2: Global Liquid Biopsy Market Dynamics Figure 3: Global Liquid Biopsy Market (by Technology), $Million, 2021 and 2032 Figure 4: Global Liquid Biopsy Market (by Workflow), $Million, 2021 and 2032 Figure 5: Global Liquid Biopsy Market (by Usage), $Million, 2021 and 2032 Figure 6: Global Liquid Biopsy Market (by Sample), $Million, 2021 and 2032 Figure 7: Global Liquid Biopsy Market (by Circulating Biomarker), $Million, 2021 and 2032 Figure 8: Global Liquid Biopsy Market (by Offering), $Million, 2021 and 2032 Figure 9: Global Liquid Biopsy Market (by Indication), $Million, 2021 and 2032 Figure 10: Global Liquid Biopsy Market (by Clinical Application), $Million, 2021 and 2032 Figure 11: Global Liquid Biopsy Market (by End User), $Million, 2021 and 2032 Figure 12: Global Liquid Biopsy Market (by Region), $Million, 2021 Figure 13: Global Liquid Biopsy Market Segmentation Figure 14: Global Liquid Biopsy Market Research Methodology Figure 15: Primary Research Methodology Figure 16: Bottom-Up Approach (Segment-Wise Analysis) Figure 17: Top-Down Approach (Segment-Wise Analysis) Figure 18: Global Liquid Biopsy Market, $Million, 2021-2032 Figure 19: Global Liquid Biopsy Market, $Million, 2021-2032 Figure 20: Pre-COVID-19 and Post-COVID-19 Scenario of Global Liquid Biopsy Market, $Million, 2020- 2026 Figure 21: Impact of COVID-19 on Liquid Biopsy Market Figure 22: Financing Analysis (by Company), $Million, FY2019-FY2022 Figure 23: Liquid Biopsy Supply Chain Analysis GLOBAL LIQUID BIOPSY MARKET Figure 24: Global Liquid Biopsy Market Dynamics Figure 25: Number of New Cases of Cancer, 2020 Figure 26: Share of Different Cancer Patients Figure 27: Synergistic Activities, 2020-2021 Figure 28: Research Funding for Different Cancer Types, 2020 Figure 29: Year-on-Year Fiscal Budget of NCI, $Million, 2015-2020 Figure 30: Share of Key Developments and Strategies, January 2019-May 2022 All rights reserved at BIS Research Inc. 14

  15. Figure 31: Synergistic Activities Share (by Company), January 2019-May 2022 Figure 32: Acquisitions Share (by Company), January 2019-May 2022 Figure 33: Funding and Business Expansion Activities (by Company), January 2019-May 2022 Figure 34: Service/Product Launches (by Company), January 2019-May 2022 Figure 35: Global Liquid Biopsy Market Share Analysis (by Product Manufacturers), 2020 and 2021 Figure 36: Global Liquid Biopsy Market Share Analysis (Service Providers), 2020 and 2021 Figure 37: Global Liquid Biopsy Market (by Offering) Figure 38: Share of Global Liquid Biopsy Market (by Offering), $Million, 2021 and 2032 Figure 39: Global Liquid Biopsy Market (Testing Service), $Million, 2021-2032 Figure 40: Global Liquid Biopsy Market (Kits), $Million, 2021-2032 Figure 41: Global Liquid Biopsy Market (Platform), $Million, 2021-2032 Figure 42: Global Liquid Biopsy Market (Other Consumables), $Million, 2021-2032 Figure 43: Global Liquid Biopsy Market (by Technology), $Million, 2021 and 2032 Figure 44: Global Liquid Biopsy Market (Next-Generation Sequencing), $Million, 2021-2032 Figure 45: Global Liquid Biopsy Market (Polymerase Chain Reaction), $Million, 2021-2032 Figure 46: Global Liquid Biopsy Market (Digital PCR), $Million, 2021-2032 Figure 47: Global Liquid Biopsy Market (Multiplex PCR), $Million, 2021-2032 Figure 48: Global Liquid Biopsy Market (Real-Time PCR), $Million, 2021-2032 Figure 49: Global Liquid Biopsy Market (Others), $Million, 2021-2032 Figure 50: Global Liquid Biopsy Market (Other Technologies), $Million, 2021-2032 Figure 51: Global Liquid Biopsy Market (by Emerging Technologies), $Million, 2021-2032 Figure 52: Global Liquid Biopsy Market (by Workflow) Figure 53: Global Liquid Biopsy Market (by Workflow), 2021 vs. 2032 Figure 54: Global Liquid Biopsy Market (Sample Preparation), 2021-2032 Figure 55: Global Liquid Biopsy Market (Library Preparation), 2021-2032 Figure 56: Global Liquid Biopsy Market (Sequencing), 2021-2032 GLOBAL LIQUID BIOPSY MARKET Figure 57: Global Liquid Biopsy Market (Data Analysis and Management), 2021-2032 Figure 58: Global Liquid Biopsy Market (by Usage) Figure 59: Global Liquid Biopsy Market (by Usage), 2021 vs. 2032 Figure 60: Global Liquid Biopsy Market (Clinical), 2021-2032 Figure 61: Global Liquid Biopsy Market (Research), 2021-2032 Figure 62: Global Liquid Biopsy Market (by Sample) Figure 63: Global Liquid Biopsy Market (by Sample), 2021 vs. 2032 All rights reserved at BIS Research Inc. 15

  16. Figure 64: Global Liquid Biopsy Market (Blood), 2021-2032 Figure 65: Global Liquid Biopsy Market (Urine), 2021-2032 Figure 66: Global Liquid Biopsy Market (Saliva), 2021-2032 Figure 67: Global Liquid Biopsy Market (by Others), 2021-2032 Figure 68: Global Liquid Biopsy Market (by Circulating Biomarker Figure 69: Global Liquid Biopsy Market (by Circulating Biomarker), 2021 vs. 2032 Figure 70: Global Liquid Biopsy Market (Circulating Tumor Cells), 2021-2032 Figure 71: Global Liquid Biopsy Market (Cell-Free DNA), 2021-2032 Figure 72: Global Liquid Biopsy Market (Circulating Cell-Free RNAs), 2021-2032 Figure 73: Global Liquid Biopsy Market (Exosomes and Extracellular Vesicles), 2021-2032 Figure 74: Global Liquid Biopsy Market (by Other Circulating Biomarkers), 2021-2032 Figure 75: Global Liquid Biopsy Market (by Indication) Figure 76: Global Liquid Biopsy Market (by Indication), 2021 vs. 2032 Figure 77: Global Liquid Biopsy Market (Breast Cancer), 2021-2032 Figure 78: Global Liquid Biopsy Market (Prostate Cancer), 2021-2032 Figure 79: Global Liquid Biopsy Market (Lung Cancer), 2021-2032 Figure 80: Global Liquid Biopsy Market (Colorectal Cancer), 2021-2032 Figure 81: Global Liquid Biopsy Market (Melanoma), 2021-2032 Figure 82: Global Liquid Biopsy Market (by Other Types of Cancer), 2021-2032 Figure 83: Global Liquid Biopsy Market (Non-Oncology Disorder), 2021-2032 Figure 84: Global Liquid Biopsy Market (by Clinical Application) Figure 85: Global Liquid Biopsy Market (by Clinical Application), 2021 vs. 2032 Figure 86: Global Liquid Biopsy Market (Treatment Monitoring), 2021-2032 Figure 87: Global Liquid Biopsy Market (Prognosis and Recurrence Monitoring), 2021-2032 Figure 88: Global Liquid Biopsy Market (Treatment Selection), 2021-2032 Figure 89: Global Liquid Biopsy Market (Diagnosis and Screening), 2021-2032 GLOBAL LIQUID BIOPSY MARKET Figure 90: Global Liquid Biopsy Market (by End User), 2021 vs. 2032 Figure 91: Global Liquid Biopsy Market (Academic and Research Institutions), $Million, 2021-2032 Figure 92: Global Liquid Biopsy Market (Clinical Laboratories), $Million, 2021-2032 Figure 93: Global Liquid Biopsy Market (Pharmaceutical and Biotechnology Companies), $Million, 2021- 2032 Figure 94: Global Liquid Biopsy Market (Other End Users), $Million, 2021-2032 Figure 95: Global Liquid Biopsy Market (by Region), $Million, 2021-2032 All rights reserved at BIS Research Inc. 16

  17. Figure 96: Global Liquid Biopsy Market (by North America), 2021 vs. 2032 Figure 97: North America Liquid Biopsy Market, $Million, 2021-2032 Figure 98: North America Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 99: Market Dynamics of North America Liquid Biopsy Market Figure 100: U.S. Liquid Biopsy Market, 2021-2032 Figure 101: U.S. Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 102: Canada Liquid Biopsy Market, 2021-2032 Figure 103: Canada Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 104: Global Liquid Biopsy Market (by Europe), 2021 vs. 2032 Figure 105: Europe Liquid Biopsy Market, $Million, 2021-2032 Figure 106: Europe Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 107: Market Dynamics of the Europe Liquid Biopsy Market Figure 108: Germany Liquid Biopsy Market, 2021-2032 Figure 109: Germany Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 110: France Liquid Biopsy Market, 2021-2032 Figure 111: France Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 112: U.K. Liquid Biopsy Market, 2021-2032 Figure 113: U.K. Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 114: Italy Liquid Biopsy Market, 2021-2032 Figure 115: Italy Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 116: Spain Liquid Biopsy Market, 2021-2032 Figure 117: Spain Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 118: Rest-of-Europe Liquid Biopsy Market, 2021-2032 Figure 119: Rest-of-Europe Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 120: Global Liquid Biopsy Market (by Asia-Pacific), 2021 vs. 2032 Figure 121: Asia-Pacific Liquid Biopsy Market, $Million, 2021-2032 GLOBAL LIQUID BIOPSY MARKET Figure 122: Asia-Pacific Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 123: Market Dynamics of Asia-Pacific Liquid Biopsy Market Figure 124: China Liquid Biopsy Market, 2021-2032 Figure 125: China Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 126: Japan Liquid Biopsy Market, 2021-2032 Figure 127: Japan Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 128: India Liquid Biopsy Market, 2021-2032 All rights reserved at BIS Research Inc. 17

  18. Figure 129: India Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 130: Australia Liquid Biopsy Market, 2021-2032 Figure 131: Australia Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 132: South Korea Liquid Biopsy Market, 2021-2032 Figure 133: South Korea Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 134: Singapore Liquid Biopsy Market, 2021-2032 Figure 135: Singapore Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 136: Rest-of-Asia-Pacific Liquid Biopsy Market, 2021-2032 Figure 137: Rest-of-Asia-Pacific Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 138: Global Liquid Biopsy Market (by Latin America and Middle East), 2021 vs. 2032 Figure 139: Latin America and Middle East Liquid Biopsy Market, $Million, 2021-2032 Figure 140: Latin America and Middle East Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 141: Market Dynamics of Latin America and Middle Eastern Liquid Biopsy Market Figure 142: Brazil Liquid Biopsy Market, 2021-2032 Figure 143: Brazil Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 144: Mexico Liquid Biopsy Market, 2021-2032 Figure 145: Mexico Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 146: Saudi Arabia Liquid Biopsy Market, 2021-2032 Figure 147: Saudi Arabia Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 148: Rest-of-Latin America and Middle East Liquid Biopsy Market, 2021-2032 Figure 149: Rest-of-Latin America and Middle East Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 150: Rest-of-the-World Liquid Biopsy Market, 2021-2032 Figure 151: Rest-of-the-World Liquid Biopsy Market, Thousand Units, 2021-2032 Figure 152: Total Number of Companies Profiled Figure 153: Abcodia Ltd.: Product Portfolio Figure 154: Bio-Rad Laboratories, Inc.: Overall Product Portfolio GLOBAL LIQUID BIOPSY MARKET Figure 155: Bio-Rad Laboratories, Inc.: Overall Financials, 2019-2021 Figure 156: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2019-2021 Figure 157: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2019-2021 Figure 158: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2019-2021 Figure 159: Biocept, Inc.: Portfolio Figure 160: Biocept, Inc.: Overall Financials, 2019-2021 Figure 161: Biocept, Inc.: R&D Expenditure, 2019-2021 All rights reserved at BIS Research Inc. 18

  19. Figure 162: Dxcover Limited: Product Portfolio Figure 163: Dxcover Limited: Dxcover Platform Workflow Figure 164: Dxcover Limited: Collaboration and Partnership of Dxcover Limited Figure 165: Elypta: Product Portfolio Figure 166: Epic Sciences: Portfolio Figure 167: F. Hoffmann-La Roche Ltd: Overall Product Portfolio Figure 168: F. Hoffmann-La Roche Ltd: Overall Financials, 2019-2021 Figure 169: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2019-2021 Figure 170: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2019-2021 Figure 171: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2020 Figure 172: Guardant Health: Portfolio Figure 173: Guardant Health: Overall Financials, 2019-2021 Figure 174: Guardant Health: Sales (by Segment), 2019-2021 Figure 175: Guardant Health: Sales (by Region), 2019-2021 Figure 176: Guardant Health: R&D Expenditure, 2019-2021 Figure 177: Illumina, Inc.: Product Portfolio Figure 178: Illumina, Inc.: Overall Financials, $Million, 2019-2021 Figure 179: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 180: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021 Figure 181: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021 Figure 182: Laboratory Corporation of America Holdings: Overall Product Portfolio Figure 183: Laboratory Corporation of America Holdings: Overall Financials, 2019-2021 Figure 184: Laboratory Corporation of America Holdings: Revenue (by Segment), 2019-2021 Figure 185: Laboratory Corporation of America Holdings: Revenue (by Region), 2019-2021 Figure 186: LungLife AI, Inc.: Portfolio Figure 187: Micronoma: Oncobiota Platform Design Overview GLOBAL LIQUID BIOPSY MARKET Figure 188: Micronoma: Research Partners of Micronoma Figure 189: Micronoma: Product Portfolio Figure 190: Natera, Inc.: Product Portfolio Figure 191: Natera, Inc.: Overall Financials, 2019-2021 Figure 192: Natera, Inc.: Sales (by Segment), 2019-2021 Figure 193: Natera, Inc.: R&D Expenditure, 2019-2021 Figure 194: Neogenomics Laboratories: Overall Product Portfolio All rights reserved at BIS Research Inc. 19

  20. Figure 195: Neogenomics Laboratories: Overall Financials, 2019-2021 Figure 196: Neogenomics Laboratories: Revenue (by Segment), 2019-2021 Figure 197: Neogenomics Laboratories: R&D Expenditure, 2019-2021 Figure 198: PerkinElmer Inc.: Product Portfolio Figure 199: PerkinElmer Inc.: Overall Financials, $Million, 2019-2021 Figure 200: PerkinElmer Inc.: Revenue (by Segment), $Million, 2019-2021 Figure 201: PerkinElmer Inc.: Revenue (by Region), $Million, 2019-2021 Figure 202: PerkinElmer Inc.: R&D Expenditure, $Million, 2019-2021 Figure 203: QIAGEN: Overall Product Portfolio Figure 204: QIAGEN: Overall Financials, 2019-2021 Figure 205: QIAGEN: Revenue (by Segment), 2019-2021 Figure 206: QIAGEN: Revenue (by Region), 2019-2021 Figure 207: QIAGEN: R&D Expenditure, 2019-2021 Figure 208: Sysmex Corporation: Overall Product Portfolio Figure 209: Sysmex Corporation: Overall Financials, 2018-2020 Figure 210: Sysmex Corporation: Revenue (by Region), 2018-2020 Figure 211: Sysmex Corporation: R&D Expenditure, 2018-2020 Figure 212: Thermo Fisher Scientific Inc.: Product Portfolio Figure 213: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021 Figure 214: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2019-2021 Figure 215: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021 Figure 216: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021 GLOBAL LIQUID BIOPSY MARKET All rights reserved at BIS Research Inc. 20

  21. List of Tables Table 1: Most Common Cancers Table 2: Global Liquid Biopsy Market (by Region), $Million, 2021-2032 Table 3: COVID-19 Impact on Global Liquid Biopsy Market Table 4: Products and Services Launched by Various Key Players for Liquid Biopsy Research Table 5: Launched Liquid Biopsy Tests from Major Players Table 6: Reimbursement Scenario for Key Players' Offerings in the Global Liquid Biopsy Market Table 7: Global Liquid Biopsy Market: Key Players Patent Portfolio Table 8: Liquid Biopsy Product Mapping Analysis (by Technology) Table 9: Liquid Biopsy Product Mapping Analysis (by Sample) Table 10:Liquid Biopsy Product Mapping Analysis (by Circulating Biomarker) Table 11:Liquid Biopsy Product Mapping Analysis (by Application) Table 12:Government Initiatives for Liquid Biopsies Table 13:Pricing List of Key Players’ Liquid Biopsies Table 14:List of Companies Providing Testing Services Table 15:List of Companies Providing Kits Table 16:List of Companies Providing Platform Table 17:List of Companies Providing Other Consumables GLOBAL LIQUID BIOPSY MARKET All rights reserved at BIS Research Inc. 21

  22. BIS Research Offerings: We are on a mission to harness the potential of disruptive technologies to make businesses thrive in today’s digital age. We have a vision to be a leading and a preferred knowledge partner for corporates and institutions worldwide and assist them with market intelligence in the area of emerging technologies, advisories, and other innovative solutions. Know More Know More Know More GLOBAL LIQUID BIOPSY MARKET Know More All rights reserved at BIS Research Inc. 22

  23. Disclaimer BIS Research Inc. provides valuable market intelligence to an exclusive group of customers in response to orders. The report is licensed for the customer's internal use only and is subject to restrictions set henceforth. This document and its contents are confidential and may not be further distributed, published or reproduced, in whole or in part, by any medium or in any form for any purpose, without the express written consent of BIS Research Inc. Customer will not disclose the contents of the report, whether directly in any media or indirectly through incorporation in a database, marketing list, report or otherwise, or use or permit the use of Information to generate any statistical or other information that is or will be provided to third parties; or voluntarily produce Information in legal proceedings. Market reports are based on expectations, estimates and projections as of the date such information is available. Any recommendation contained in this report may not be suitable for all investors or businesses. The market conclusions drawn are necessarily based upon a number of estimates and assumptions that, while considered reasonable by BIS Research Inc. as of the date of such statements, are inherently subject to market fluctuations and business, economic and competitive uncertainties, and contingencies For more details regarding permission, please contact us: Email: sales@bisresearch.com Tel: +1 510 404 8135 GLOBAL LIQUID BIOPSY MARKET All rights reserved at BIS Research Inc. 23

  24. BIS RESEARCH INC. 39111 Paseo Padre PKWY, Suite 313 Fremont, CA 94538 -1686 E-mail: hello@bisresearch.com | Call Us: +1-510-404-8135 GLOBAL LIQUID BIOPSY MARKET Global Delivery Center Tower B First Floor, Tapasya Corporate Heights, Greater Noida Expressway, Sector 126, Noida, U.P., 201303, India Tel: +91 120 4261540 / 4261544 www.bisresearch.com All rights reserved at BIS Research Inc. 24

More Related